Nurix Therapeutics Inc (NAS:NRIX)
$ 15.9 0.95 (6.35%) Market Cap: 970.97 Mil Enterprise Value: 698.12 Mil PE Ratio: 0 PB Ratio: 4.35 GF Score: 67/100

Nurix Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 11:00PM GMT
Release Date Price: $9.96 (+0.91%)
Eric Joseph JPMorgan;Analyst

All right. Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Nurix Therapeutics, and presenting on behalf of the company is CEO, Arthur Sands. There is a Q&A session after the presentation. If you got a question, we'll bring a mic to you. For those tuning in via the webcast, you can also submit questions via the portal. So with that, Arthur, thanks for joining us.

Arthur Sands Nurix Therapeutics Inc;President
CEO, and Board Director

Thank you, Eric. And I'd like to thank the entire JPMorgan team for inviting us, and for another great JPMorgan conference this year. I will be making certain forward-looking statements, and we refer you to our filings with the SEC regarding the risk factors that face our business.

So at Nurix, we are focused on targeted protein modulation, a new approach to making small molecule agents that can do one of two things -- either harness any E3 ligase as pictured here in the center of the screen -- harness it in order

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot